Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-miR-29b-3p | ABL1 | 0.27 | 0.74029 | -0.21 | 0.734 | miRNATAP | -0.15 | 0 | NA | |
| 2 | hsa-miR-30e-5p | ABL1 | 0.74 | 0.51197 | -0.21 | 0.734 | MirTarget; miRNATAP | -0.12 | 0 | NA | |
| 3 | hsa-miR-140-3p | ANAPC1 | 0.56 | 0.53812 | 0.3 | 0.50716 | MirTarget | -0.1 | 4.0E-5 | NA | |
| 4 | hsa-miR-100-5p | ANAPC11 | 0.16 | 0.88382 | 0.03 | 0.95793 | miRNAWalker2 validate | -0.3 | 0 | NA | |
| 5 | hsa-miR-146b-5p | ANAPC13 | 0.88 | 0.28494 | -0.32 | 0.55225 | miRanda | -0.13 | 0 | NA | |
| 6 | hsa-miR-139-5p | ANAPC7 | -0.29 | 0.60387 | 0.04 | 0.93977 | miRanda | -0.12 | 0 | NA | |
| 7 | hsa-miR-181a-5p | ATM | 0.21 | 0.83306 | -0.05 | 0.92324 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.21 | 0 | 21102523; 23656790; 24531888; 27150990; 26113450 | Ataxia telangiectasia mutated ATM a target gene of miR-181 exhibited reduced expression in mammospheres and upon TGF-β treatment;We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers and their expression correlates inversely with ATM levels;Ataxia-telangiectasia mutation ATM was predicted as a target gene of miR-181a with bioinformatics analysis and was verified by lucifersae reporter assay; A luciferase reporter assay demonstrated that ATM was a direct target of miR-181a miR-181a mimics transfection down regulated ATM mRNA and protein expression; There was inverse correlation between miR-181a and ATM protein expression in gastric cancer and normal gastric tissues; Our study demonstrates that over-expression of miR-181a might be involved in development of gastric cancer by promoting proliferation and inhibiting apoptosis probably through directly targeting ATM miR-181a modulation may be a potential strategy for the development of miRNA-based therapy of gastric cancer;MiR 181a Promotes Proliferation of Human Acute Myeloid Leukemia Cells by Targeting ATM; Dual luciferase reporter gene assay showed that miR-181a significantly suppressed the reporter gene activity containing ATM 3'-UTR by about 56.8% P < 0.05 but it didn't suppress the reporter gene activity containing 3'-UTR ATM mutation; Western blot showed that miR-181a significantly downregulated the expression of ATM in human leukemia cells; It is also found that miR-181a was significantly increased in AML which showed a negative correlation with ATM expression; miR-181a promotes cell proliferation in AML by regulating the tumor suppressor ATM thus it plays the role as oncogene in pathogenesis of AML;miR 181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM; Pediatric AML patients and healthy controls were enrolled and the expression of miR-181a and ataxia telangiectasia mutated ATM in tissues were examined using quantitative PCR; Moreover cell proliferation and cell cycle were evaluated in several cell lines HL60 NB4 and K562 by using flow cytometry after transfected with miR-181a mimics and inhibitors or ATM siRNA and control siRNA; Finally ATM as the potential target protein of miR-181a was examined; We found that miR-181a was significantly increased in pediatric AML which showed an inverse association with ATM expression; Luciferase activity of the reporter construct identified ATM as the direct molecular target of miR-181a; The results revealed novel mechanism through which miR-181a regulates G1/S transition and cell proliferation in pediatric AML by regulating the tumor suppressor ATM providing insights into the molecular mechanism in pediatric AML |
| 8 | hsa-miR-181b-5p | ATM | 0.52 | 0.50566 | -0.05 | 0.92324 | MirTarget | -0.22 | 0 | 21102523; 23656790 | Ataxia telangiectasia mutated ATM a target gene of miR-181 exhibited reduced expression in mammospheres and upon TGF-β treatment;We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers and their expression correlates inversely with ATM levels |
| 9 | hsa-miR-181d-5p | ATM | 0.55 | 0.20485 | -0.05 | 0.92324 | MirTarget | -0.12 | 0 | NA | |
| 10 | hsa-miR-18a-5p | ATM | 2.3 | 0 | -0.05 | 0.92324 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.12 | 0 | 23857602; 23437304; 25963391; 23229340 | Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases |
| 11 | hsa-miR-21-5p | ATM | -0.14 | 0.92885 | -0.05 | 0.92324 | mirMAP | -0.23 | 0 | 26289851 | MiR-21 is an oncomiR that is overexpressed in nearly all cancers including ATC; Hence suppression of miR-21 could pave the way for ATC therapy |
| 12 | hsa-miR-140-3p | ATR | 0.56 | 0.53812 | 0.18 | 0.71274 | PITA | -0.14 | 0 | NA | |
| 13 | hsa-miR-361-5p | ATR | 0.3 | 0.67981 | 0.18 | 0.71274 | miRanda | -0.24 | 0 | NA | |
| 14 | hsa-miR-374a-5p | ATR | 0.47 | 0.30955 | 0.18 | 0.71274 | mirMAP | -0.11 | 0.00014 | NA | |
| 15 | hsa-miR-10b-3p | BUB1 | -0.78 | 0.05898 | 1.35 | 0.00016 | MirTarget | -0.88 | 0 | NA | |
| 16 | hsa-miR-139-5p | BUB1 | -0.29 | 0.60387 | 1.35 | 0.00016 | miRanda | -0.68 | 0 | NA | |
| 17 | hsa-miR-199a-5p | BUB1 | -0.59 | 0.53489 | 1.35 | 0.00016 | miRanda | -0.38 | 0 | NA | |
| 18 | hsa-miR-199b-5p | BUB1 | -0.49 | 0.51436 | 1.35 | 0.00016 | miRanda | -0.59 | 0 | NA | |
| 19 | hsa-miR-495-3p | BUB1 | 0.04 | 0.88707 | 1.35 | 0.00016 | MirTarget | -0.42 | 0 | NA | |
| 20 | hsa-miR-653-5p | BUB1 | -0.29 | 0.40635 | 1.35 | 0.00016 | MirTarget | -0.19 | 5.0E-5 | NA | |
| 21 | hsa-miR-215-5p | BUB1B | 0.47 | 0.06524 | 0.95 | 0.00484 | miRNAWalker2 validate | -0.12 | 0.00478 | NA | |
| 22 | hsa-miR-22-3p | BUB1B | 0.05 | 0.97344 | 0.95 | 0.00484 | miRNAWalker2 validate | -0.41 | 0 | NA | |
| 23 | hsa-miR-486-5p | BUB1B | 0.22 | 0.72625 | 0.95 | 0.00484 | miRanda | -0.33 | 0 | NA | |
| 24 | hsa-miR-139-5p | BUB3 | -0.29 | 0.60387 | -0.36 | 0.57227 | miRanda | -0.19 | 0 | NA | |
| 25 | hsa-let-7b-3p | CCNA2 | -0.11 | 0.8248 | 1.39 | 0.00016 | MirTarget | -0.24 | 0 | NA | |
| 26 | hsa-let-7b-5p | CCNA2 | -0.33 | 0.80106 | 1.39 | 0.00016 | miRNAWalker2 validate; miRTarBase | -0.52 | 0 | NA | |
| 27 | hsa-miR-199a-5p | CCNA2 | -0.59 | 0.53489 | 1.39 | 0.00016 | miRanda | -0.38 | 0 | NA | |
| 28 | hsa-miR-199b-5p | CCNA2 | -0.49 | 0.51436 | 1.39 | 0.00016 | miRanda | -0.5 | 0 | NA | |
| 29 | hsa-miR-218-5p | CCNA2 | 0.01 | 0.99053 | 1.39 | 0.00016 | MirTarget | -0.49 | 0 | NA | |
| 30 | hsa-miR-22-3p | CCNA2 | 0.05 | 0.97344 | 1.39 | 0.00016 | MirTarget | -0.25 | 0.00339 | 25596928 | The sequence of miR-22 which is conserved in mice rats humans and other mammalians aligns with the sequence of 3'-UTR of CCNA2; Chenodeoxycholic acid treatment and miR-22 mimics reduced CCNA2 protein and increased the number of G0/G1 Huh7 and HCT116 cells; In humans the expression levels of miR-22 and CCNA2 are inversely correlated in liver and colon cancers |
| 31 | hsa-miR-29a-3p | CCNA2 | 0.46 | 0.68374 | 1.39 | 0.00016 | MirTarget | -0.45 | 0 | NA | |
| 32 | hsa-miR-29c-3p | CCNA2 | -0.64 | 0.52285 | 1.39 | 0.00016 | MirTarget | -0.43 | 0 | NA | |
| 33 | hsa-miR-320a | CCNA2 | 0.24 | 0.77369 | 1.39 | 0.00016 | miRanda | -0.21 | 0.0016 | NA | |
| 34 | hsa-miR-34c-5p | CCNA2 | -0.74 | 0.01835 | 1.39 | 0.00016 | miRanda | -0.29 | 0 | NA | |
| 35 | hsa-miR-486-5p | CCNA2 | 0.22 | 0.72625 | 1.39 | 0.00016 | miRanda | -0.26 | 0 | NA | |
| 36 | hsa-let-7b-5p | CCNB1 | -0.33 | 0.80106 | 0.67 | 0.15126 | miRNAWalker2 validate | -0.39 | 0 | NA | |
| 37 | hsa-miR-139-5p | CCNB1 | -0.29 | 0.60387 | 0.67 | 0.15126 | miRanda | -0.49 | 0 | NA | |
| 38 | hsa-miR-140-5p | CCNB1 | 0.78 | 0.10115 | 0.67 | 0.15126 | miRanda | -0.15 | 0.00114 | NA | |
| 39 | hsa-let-7a-5p | CCNB2 | -0.25 | 0.85781 | 1.39 | 0.00014 | miRNAWalker2 validate | -0.62 | 0 | NA | |
| 40 | hsa-let-7b-5p | CCNB2 | -0.33 | 0.80106 | 1.39 | 0.00014 | miRNAWalker2 validate | -0.54 | 0 | NA | |
| 41 | hsa-let-7c-5p | CCNB2 | 0.07 | 0.94922 | 1.39 | 0.00014 | miRNAWalker2 validate | -0.66 | 0 | NA | |
| 42 | hsa-let-7i-5p | CCND1 | 0.49 | 0.5398 | -1.64 | 0.03536 | miRNATAP | -0.76 | 0 | NA | |
| 43 | hsa-miR-106a-5p | CCND1 | 1.16 | 0.00089 | -1.64 | 0.03536 | MirTarget; miRNATAP | -0.17 | 0 | NA | |
| 44 | hsa-miR-106b-5p | CCND1 | 1.05 | 0.13909 | -1.64 | 0.03536 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.26 | 0 | NA | |
| 45 | hsa-miR-142-3p | CCND1 | 1.18 | 0.19612 | -1.64 | 0.03536 | miRanda | -0.11 | 0.00024 | 23619912 | Transfection of miR-142-3p mimics in colon cancer cells downregulated cyclin D1 expression induced G1 phase cell cycle arrest and elevated the sensitivity of the cells to 5-fluorouracil |
| 46 | hsa-miR-142-5p | CCND1 | 1.23 | 0.01501 | -1.64 | 0.03536 | PITA | -0.21 | 0 | NA | |
| 47 | hsa-miR-150-5p | CCND1 | 1.17 | 0.17525 | -1.64 | 0.03536 | mirMAP | -0.19 | 0 | NA | |
| 48 | hsa-miR-155-5p | CCND1 | 1.13 | 0.13193 | -1.64 | 0.03536 | miRNAWalker2 validate | -0.3 | 0 | 26955820 | MicroRNA 155 expression inversely correlates with pathologic stage of gastric cancer and it inhibits gastric cancer cell growth by targeting cyclin D1 |
| 49 | hsa-miR-15b-5p | CCND1 | 0.69 | 0.30443 | -1.64 | 0.03536 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.13 | 0.00922 | NA | |
| 50 | hsa-miR-17-5p | CCND1 | 1.81 | 0.01774 | -1.64 | 0.03536 | miRNAWalker2 validate; MirTarget; TargetScan; miRNATAP | -0.24 | 0 | 26431674 | Bioinformatics Prediction and In Vitro Analysis Revealed That miR 17 Targets Cyclin D1 mRNA in Triple Negative Breast Cancer Cells; In this study using bioinformatic analyses miR-17 was selected as it targets the 3'UTR of CCND1 gene with the highest score; After lentiviral transduction of miR-17 to the target cells gene expression analysis showed decreased expression of CCND1 gene |
| 51 | hsa-miR-186-5p | CCND1 | 1.04 | 0.14871 | -1.64 | 0.03536 | mirMAP | -0.49 | 0 | NA | |
| 52 | hsa-miR-19a-3p | CCND1 | 1.47 | 0.00036 | -1.64 | 0.03536 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.22 | 0 | 25985117 | Moreover miR-19a might play inhibitory roles in HCC malignancy via regulating Cyclin D1 expression |
| 53 | hsa-miR-19b-1-5p | CCND1 | 1.37 | 0 | -1.64 | 0.03536 | miRNAWalker2 validate; miRTarBase | -0.21 | 0 | NA | |
| 54 | hsa-miR-19b-3p | CCND1 | 1.16 | 0.06285 | -1.64 | 0.03536 | miRNATAP | -0.25 | 0 | NA | |
| 55 | hsa-miR-20a-5p | CCND1 | 1.44 | 0.04652 | -1.64 | 0.03536 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.22 | 0 | NA | |
| 56 | hsa-miR-23b-3p | CCND1 | 0.33 | 0.69728 | -1.64 | 0.03536 | miRNATAP | -0.21 | 0.00024 | NA | |
| 57 | hsa-miR-29a-3p | CCND1 | 0.46 | 0.68374 | -1.64 | 0.03536 | mirMAP | -0.36 | 0 | NA | |
| 58 | hsa-miR-340-5p | CCND1 | 0.36 | 0.35065 | -1.64 | 0.03536 | mirMAP | -0.16 | 0.00211 | NA | |
| 59 | hsa-miR-374a-5p | CCND1 | 0.47 | 0.30955 | -1.64 | 0.03536 | MirTarget | -0.56 | 0 | 27191497 | microRNA 374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway; Furthermore luciferase reporter assays confirmed that miR-374a could directly reduce CCND1; We examined miR-374a levels by in situ hybridization and its correlation with CCND1 expression in CRC tumor tissues; High miR-374a expression with low level of CCND1 was protective factor in CRC; Together these findings indicate that miR-374a inactivates the PI3K/AKT axis by inhibiting CCND1 suppressing of colon cancer progression |
| 60 | hsa-miR-374b-5p | CCND1 | 0.48 | 0.36577 | -1.64 | 0.03536 | miRNAWalker2 validate; MirTarget | -0.53 | 0 | NA | |
| 61 | hsa-miR-424-5p | CCND1 | 0.58 | 0.32687 | -1.64 | 0.03536 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.17 | 1.0E-5 | NA | |
| 62 | hsa-miR-495-3p | CCND1 | 0.04 | 0.88707 | -1.64 | 0.03536 | MirTarget | -0.27 | 0 | NA | |
| 63 | hsa-miR-511-5p | CCND1 | 1.26 | 7.0E-5 | -1.64 | 0.03536 | MirTarget | -0.22 | 0 | NA | |
| 64 | hsa-miR-589-3p | CCND1 | 0.87 | 0 | -1.64 | 0.03536 | MirTarget | -0.12 | 0.00155 | NA | |
| 65 | hsa-miR-590-3p | CCND1 | 1.01 | 0 | -1.64 | 0.03536 | mirMAP | -0.22 | 0 | NA | |
| 66 | hsa-miR-9-5p | CCND1 | 2.31 | 0.01107 | -1.64 | 0.03536 | miRNAWalker2 validate | -0.16 | 0 | NA | |
| 67 | hsa-miR-92a-3p | CCND1 | 1.23 | 0.30313 | -1.64 | 0.03536 | miRNAWalker2 validate | -0.36 | 0 | NA | |
| 68 | hsa-miR-93-5p | CCND1 | 0.94 | 0.3985 | -1.64 | 0.03536 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.16 | 0.00197 | NA | |
| 69 | hsa-miR-942-5p | CCND1 | 1.66 | 0 | -1.64 | 0.03536 | MirTarget | -0.26 | 0 | NA | |
| 70 | hsa-let-7a-3p | CCND2 | 0.31 | 0.49951 | -0.07 | 0.88928 | mirMAP | -0.22 | 0 | 20418948 | MicroRNA let 7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2 |
| 71 | hsa-let-7e-5p | CCND2 | -0.08 | 0.93271 | -0.07 | 0.88928 | miRNATAP | -0.17 | 0.00031 | NA | |
| 72 | hsa-miR-106a-5p | CCND2 | 1.16 | 0.00089 | -0.07 | 0.88928 | miRNATAP | -0.12 | 1.0E-5 | NA | |
| 73 | hsa-miR-106b-5p | CCND2 | 1.05 | 0.13909 | -0.07 | 0.88928 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.32 | 0 | NA | |
| 74 | hsa-miR-130b-5p | CCND2 | 1.39 | 0 | -0.07 | 0.88928 | mirMAP | -0.11 | 1.0E-5 | NA | |
| 75 | hsa-miR-141-3p | CCND2 | 0.52 | 0.54365 | -0.07 | 0.88928 | MirTarget; TargetScan | -0.3 | 0 | NA | |
| 76 | hsa-miR-151a-3p | CCND2 | 0.49 | 0.62227 | -0.07 | 0.88928 | mirMAP | -0.18 | 0.00011 | NA | |
| 77 | hsa-miR-15a-5p | CCND2 | 0.34 | 0.60504 | -0.07 | 0.88928 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.38 | 0 | NA | |
| 78 | hsa-miR-15b-5p | CCND2 | 0.69 | 0.30443 | -0.07 | 0.88928 | miRNATAP | -0.2 | 0 | NA | |
| 79 | hsa-miR-16-5p | CCND2 | 0.61 | 0.44106 | -0.07 | 0.88928 | miRNAWalker2 validate; miRNATAP | -0.13 | 0.0015 | NA | |
| 80 | hsa-miR-17-5p | CCND2 | 1.81 | 0.01774 | -0.07 | 0.88928 | miRNAWalker2 validate; miRTarBase; TargetScan; miRNATAP | -0.22 | 0 | NA | |
| 81 | hsa-miR-182-5p | CCND2 | -0.35 | 0.79413 | -0.07 | 0.88928 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.33 | 0 | NA | |
| 82 | hsa-miR-183-5p | CCND2 | 0.2 | 0.86335 | -0.07 | 0.88928 | miRNATAP | -0.3 | 0 | NA | |
| 83 | hsa-miR-185-5p | CCND2 | 0.41 | 0.43546 | -0.07 | 0.88928 | MirTarget; miRNATAP | -0.25 | 0 | NA | |
| 84 | hsa-miR-191-5p | CCND2 | -0.18 | 0.82875 | -0.07 | 0.88928 | MirTarget | -0.19 | 0 | NA | |
| 85 | hsa-miR-19a-3p | CCND2 | 1.47 | 0.00036 | -0.07 | 0.88928 | MirTarget; miRNATAP | -0.19 | 0 | NA | |
| 86 | hsa-miR-19b-3p | CCND2 | 1.16 | 0.06285 | -0.07 | 0.88928 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.17 | 0 | NA | |
| 87 | hsa-miR-200a-3p | CCND2 | 0.3 | 0.67136 | -0.07 | 0.88928 | MirTarget | -0.26 | 0 | NA | |
| 88 | hsa-miR-20a-5p | CCND2 | 1.44 | 0.04652 | -0.07 | 0.88928 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.24 | 0 | NA | |
| 89 | hsa-miR-20b-5p | CCND2 | 0.53 | 0.21452 | -0.07 | 0.88928 | miRNATAP | -0.1 | 0 | NA | |
| 90 | hsa-miR-21-3p | CCND2 | 0.12 | 0.90444 | -0.07 | 0.88928 | mirMAP | -0.13 | 2.0E-5 | NA | |
| 91 | hsa-miR-29b-3p | CCND2 | 0.27 | 0.74029 | -0.07 | 0.88928 | MirTarget; miRNATAP | -0.17 | 0 | 22330340; 24130168 | In addition to CCND2 miR-29 also targets E2F7 another cell cycle regulator;We further demonstrated that miR-29 family acted as tumor suppressors through targeting CCND2 and matrix metalloproteinase-2 genes in GC |
| 92 | hsa-miR-301a-3p | CCND2 | 0.97 | 0.00057 | -0.07 | 0.88928 | miRNAWalker2 validate | -0.18 | 0 | NA | |
| 93 | hsa-miR-3065-3p | CCND2 | -0.22 | 0.65713 | -0.07 | 0.88928 | MirTarget; miRNATAP | -0.22 | 0 | NA | |
| 94 | hsa-miR-30d-3p | CCND2 | 0.27 | 0.27013 | -0.07 | 0.88928 | mirMAP | -0.28 | 0 | NA | |
| 95 | hsa-miR-320b | CCND2 | 0.71 | 0.0026 | -0.07 | 0.88928 | mirMAP; miRNATAP | -0.11 | 0.00066 | NA | |
| 96 | hsa-miR-324-3p | CCND2 | 0.75 | 0.04368 | -0.07 | 0.88928 | miRNAWalker2 validate | -0.19 | 0 | NA | |
| 97 | hsa-miR-331-5p | CCND2 | 0.4 | 0.0121 | -0.07 | 0.88928 | miRNATAP | -0.22 | 0 | NA | |
| 98 | hsa-miR-342-3p | CCND2 | -0.72 | 0.32809 | -0.07 | 0.88928 | miRNAWalker2 validate; mirMAP | -0.1 | 0.00019 | NA | |
| 99 | hsa-miR-429 | CCND2 | 0.45 | 0.43718 | -0.07 | 0.88928 | miRNATAP | -0.23 | 0 | NA | |
| 100 | hsa-miR-590-3p | CCND2 | 1.01 | 0 | -0.07 | 0.88928 | miRanda; mirMAP | -0.14 | 1.0E-5 | NA | |
| 101 | hsa-miR-590-5p | CCND2 | 1.4 | 0 | -0.07 | 0.88928 | mirMAP | -0.15 | 0 | NA | |
| 102 | hsa-miR-660-5p | CCND2 | 0.79 | 0.10863 | -0.07 | 0.88928 | mirMAP | -0.11 | 0.0034 | NA | |
| 103 | hsa-miR-7-1-3p | CCND2 | -0.14 | 0.72688 | -0.07 | 0.88928 | mirMAP | -0.14 | 0 | NA | |
| 104 | hsa-miR-93-5p | CCND2 | 0.94 | 0.3985 | -0.07 | 0.88928 | miRNATAP | -0.4 | 0 | NA | |
| 105 | hsa-miR-96-5p | CCND2 | 0.1 | 0.81662 | -0.07 | 0.88928 | TargetScan; miRNATAP | -0.31 | 0 | NA | |
| 106 | hsa-miR-125b-5p | CCNE1 | 0.09 | 0.91774 | 2.38 | 0 | miRNAWalker2 validate | -0.38 | 0 | NA | |
| 107 | hsa-miR-195-5p | CCNE1 | -0.13 | 0.8022 | 2.38 | 0 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.62 | 0 | 24402230 | Furthermore through qPCR and western blot assays we showed that overexpression of miR-195-5p reduced CCNE1 mRNA and protein levels respectively |
| 108 | hsa-miR-26a-5p | CCNE1 | -0.05 | 0.95817 | 2.38 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.62 | 0 | 22094936 | Cell cycle regulation and CCNE1 and CDC2 were the only significant overlapping pathway and genes differentially expressed between tumors with high and low levels of miR-26a and EZH2 respectively; Low mRNA levels of EZH2 CCNE1 and CDC2 and high levels of miR-26a are associated with favorable outcome on tamoxifen |
| 109 | hsa-miR-26b-5p | CCNE1 | -0.02 | 0.9773 | 2.38 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.32 | 0 | NA | |
| 110 | hsa-miR-342-5p | CCNE1 | -1 | 0.00867 | 2.38 | 0 | miRNAWalker2 validate | -0.14 | 0.00142 | NA | |
| 111 | hsa-miR-497-5p | CCNE1 | 0.02 | 0.96778 | 2.38 | 0 | MirTarget; miRNATAP | -0.38 | 0 | 24112607; 25909221; 24909281 | Western blot assays confirmed that overexpression of miR-497 reduced cyclin E1 protein levels; Inhibited cellular growth suppressed cellular migration and invasion and G1 cell cycle arrest were observed upon overexpression of miR-497 in cells possibly by targeting cyclin E1;The effect of simultaneous overexpression of miR-497 and miR-34a on the inhibition of cell proliferation colony formation and tumor growth and the downregulation of cyclin E1 was stronger than the effect of each miRNA alone; The synergistic actions of miR-497 and miR-34a partly correlated with cyclin E1 levels; These results indicate cyclin E1 is downregulated by both miR-497 and miR-34a which synergistically retard the growth of human lung cancer cells;miR 497 suppresses proliferation of human cervical carcinoma HeLa cells by targeting cyclin E1; Furthermore the target effect of miR-497 on the CCNE1 was identified by dual-luciferase reporter assay system qRT-PCR and Western blotting; Over-expressed miR-497 in HeLa cells could suppress cell proliferation by targeting CCNE1 |
| 112 | hsa-miR-26a-5p | CCNE2 | -0.05 | 0.95817 | 0.56 | 0.05682 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.63 | 0 | 24116110; 21901171 | The loss of miR 26a mediated post transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival; The in vitro and in vivo assays showed that overexpression of miR-26a resulted in cell cycle arrest inhibited cell proliferation and decreased tumor growth which was associated with cyclin E2 downregulation;We also show that enforced expression of miR-26a in AML cells is able to inhibit cell cycle progression by downregulating cyclin E2 expression |
| 113 | hsa-miR-28-3p | CCNE2 | 0.57 | 0.60357 | 0.56 | 0.05682 | PITA; miRNATAP | -0.33 | 4.0E-5 | NA | |
| 114 | hsa-miR-30a-5p | CCNE2 | -0.49 | 0.73014 | 0.56 | 0.05682 | miRNATAP | -0.39 | 0 | NA | |
| 115 | hsa-miR-30c-5p | CCNE2 | 0.29 | 0.7388 | 0.56 | 0.05682 | miRNATAP | -0.25 | 2.0E-5 | NA | |
| 116 | hsa-miR-335-3p | CCNE2 | 0.21 | 0.73517 | 0.56 | 0.05682 | mirMAP | -0.17 | 0 | NA | |
| 117 | hsa-miR-34c-5p | CCNE2 | -0.74 | 0.01835 | 0.56 | 0.05682 | miRNAWalker2 validate; miRTarBase; PITA; miRanda; miRNATAP | -0.25 | 0 | NA | |
| 118 | hsa-miR-1301-3p | CCNH | 1.13 | 0.00036 | -0.62 | 0.15896 | miRNAWalker2 validate | -0.1 | 0 | NA | |
| 119 | hsa-miR-142-5p | CCNH | 1.23 | 0.01501 | -0.62 | 0.15896 | PITA | -0.11 | 0 | NA | |
| 120 | hsa-miR-590-3p | CCNH | 1.01 | 0 | -0.62 | 0.15896 | miRanda | -0.11 | 0 | NA | |
| 121 | hsa-miR-141-3p | CDC14A | 0.52 | 0.54365 | -0.47 | 0.15652 | TargetScan; miRNATAP | -0.14 | 1.0E-5 | NA | |
| 122 | hsa-miR-148a-3p | CDC14A | 0.72 | 0.59727 | -0.47 | 0.15652 | miRNATAP | -0.2 | 1.0E-5 | NA | |
| 123 | hsa-miR-148a-5p | CDC14A | 0.75 | 0.11901 | -0.47 | 0.15652 | mirMAP | -0.19 | 1.0E-5 | NA | |
| 124 | hsa-miR-200a-3p | CDC14A | 0.3 | 0.67136 | -0.47 | 0.15652 | miRNATAP | -0.1 | 0.00072 | NA | |
| 125 | hsa-miR-429 | CDC14A | 0.45 | 0.43718 | -0.47 | 0.15652 | miRanda | -0.15 | 0 | NA | |
| 126 | hsa-miR-493-5p | CDC14A | -0.31 | 0.25802 | -0.47 | 0.15652 | miRNATAP | -0.11 | 0.00331 | NA | |
| 127 | hsa-miR-590-3p | CDC14A | 1.01 | 0 | -0.47 | 0.15652 | PITA; miRanda; mirMAP; miRNATAP | -0.15 | 0.00059 | NA | |
| 128 | hsa-let-7a-3p | CDC14B | 0.31 | 0.49951 | 0.46 | 0.21275 | miRNATAP | -0.19 | 4.0E-5 | NA | |
| 129 | hsa-miR-141-3p | CDC14B | 0.52 | 0.54365 | 0.46 | 0.21275 | mirMAP | -0.35 | 0 | NA | |
| 130 | hsa-miR-15a-5p | CDC14B | 0.34 | 0.60504 | 0.46 | 0.21275 | miRNAWalker2 validate; MirTarget | -0.48 | 0 | NA | |
| 131 | hsa-miR-15b-5p | CDC14B | 0.69 | 0.30443 | 0.46 | 0.21275 | MirTarget | -0.2 | 0 | NA | |
| 132 | hsa-miR-16-5p | CDC14B | 0.61 | 0.44106 | 0.46 | 0.21275 | miRNAWalker2 validate; MirTarget | -0.16 | 0.0003 | NA | |
| 133 | hsa-miR-17-3p | CDC14B | 1.47 | 0.04186 | 0.46 | 0.21275 | MirTarget | -0.18 | 0 | NA | |
| 134 | hsa-miR-183-5p | CDC14B | 0.2 | 0.86335 | 0.46 | 0.21275 | MirTarget | -0.37 | 0 | NA | |
| 135 | hsa-miR-185-5p | CDC14B | 0.41 | 0.43546 | 0.46 | 0.21275 | MirTarget | -0.39 | 0 | NA | |
| 136 | hsa-miR-200a-3p | CDC14B | 0.3 | 0.67136 | 0.46 | 0.21275 | mirMAP | -0.29 | 0 | NA | |
| 137 | hsa-miR-21-3p | CDC14B | 0.12 | 0.90444 | 0.46 | 0.21275 | mirMAP | -0.35 | 0 | NA | |
| 138 | hsa-miR-30d-3p | CDC14B | 0.27 | 0.27013 | 0.46 | 0.21275 | MirTarget | -0.18 | 2.0E-5 | NA | |
| 139 | hsa-miR-429 | CDC14B | 0.45 | 0.43718 | 0.46 | 0.21275 | PITA; miRanda; miRNATAP | -0.31 | 0 | NA | |
| 140 | hsa-miR-590-3p | CDC14B | 1.01 | 0 | 0.46 | 0.21275 | miRanda; mirMAP | -0.21 | 0 | NA | |
| 141 | hsa-miR-590-5p | CDC14B | 1.4 | 0 | 0.46 | 0.21275 | miRanda | -0.13 | 8.0E-5 | NA | |
| 142 | hsa-miR-215-5p | CDC20 | 0.47 | 0.06524 | 1.86 | 1.0E-5 | miRNAWalker2 validate | -0.15 | 0.00257 | NA | |
| 143 | hsa-miR-30a-5p | CDC20 | -0.49 | 0.73014 | 1.86 | 1.0E-5 | miRNAWalker2 validate | -0.42 | 0 | NA | |
| 144 | hsa-let-7a-5p | CDC25A | -0.25 | 0.85781 | 1.56 | 0 | MirTarget; TargetScan; miRNATAP | -0.56 | 0 | NA | |
| 145 | hsa-let-7b-5p | CDC25A | -0.33 | 0.80106 | 1.56 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.49 | 0 | NA | |
| 146 | hsa-let-7c-5p | CDC25A | 0.07 | 0.94922 | 1.56 | 0 | MirTarget | -0.48 | 0 | 25909324 | MicroRNA let 7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma; The aim of the present study was to determine whether the cell cycle regulator CDC25A is involved in the antitumor effect of let-7c in HCC; The luciferase reporter assay showed that CDC25A was a direct target of let-7c and that let-7c inhibited the expression of CDC25A protein by directly targeting its 3' UTR; In conclusion this study indicates that let-7c suppresses HCC progression possibly by directly targeting the cell cycle regulator CDC25A and indirectly affecting its downstream target molecules |
| 147 | hsa-miR-195-5p | CDC25A | -0.13 | 0.8022 | 1.56 | 0 | MirTarget; miRNATAP | -0.53 | 0 | NA | |
| 148 | hsa-miR-337-3p | CDC25A | -0.5 | 0.30557 | 1.56 | 0 | mirMAP | -0.35 | 0 | NA | |
| 149 | hsa-miR-34c-5p | CDC25A | -0.74 | 0.01835 | 1.56 | 0 | miRNATAP | -0.31 | 0 | 21321636 | Ectopic expression of miR-449b and miR-34c resulted in lowered adhesion activities by 28%-34% and in cell cycle arrests with increased cell number of 15.62% and 15.71% in G1 and with decreased cell number of 15.96% and 16.56% in S Cell cycle related proteins CDK6 and CDC25A were down-regulated; The decreases of CDK6 and CDC25A by miR-449b were 39% and 22% respecyively; 49% and 32% by miR-34c respectively |
| 150 | hsa-miR-497-5p | CDC25A | 0.02 | 0.96778 | 1.56 | 0 | MirTarget; miRNATAP | -0.28 | 0 | NA |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | CELL CYCLE | 76 | 1316 | 1.197e-76 | 5.569e-73 |
| 2 | CELL CYCLE PROCESS | 72 | 1081 | 1.853e-75 | 4.311e-72 |
| 3 | MITOTIC CELL CYCLE | 65 | 766 | 7.593e-73 | 1.178e-69 |
| 4 | REGULATION OF CELL CYCLE | 66 | 949 | 1.98e-68 | 2.303e-65 |
| 5 | REGULATION OF MITOTIC CELL CYCLE | 46 | 468 | 2.081e-51 | 1.937e-48 |
| 6 | CELL CYCLE PHASE TRANSITION | 37 | 255 | 4.533e-47 | 3.515e-44 |
| 7 | REGULATION OF CELL CYCLE PHASE TRANSITION | 39 | 321 | 1.282e-46 | 8.523e-44 |
| 8 | REGULATION OF CELL CYCLE PROCESS | 45 | 558 | 3.236e-46 | 1.673e-43 |
| 9 | NEGATIVE REGULATION OF CELL CYCLE | 42 | 433 | 3.006e-46 | 1.673e-43 |
| 10 | CELL CYCLE CHECKPOINT | 32 | 194 | 2.545e-42 | 1.184e-39 |
| 11 | NEGATIVE REGULATION OF CELL CYCLE PROCESS | 31 | 214 | 4.321e-39 | 1.828e-36 |
| 12 | CELL DIVISION | 38 | 460 | 8.424e-39 | 3.267e-36 |
| 13 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 30 | 199 | 2.427e-38 | 8.688e-36 |
| 14 | MITOTIC CELL CYCLE CHECKPOINT | 26 | 139 | 9.548e-36 | 3.173e-33 |
| 15 | REGULATION OF TRANSFERASE ACTIVITY | 44 | 946 | 1.273e-34 | 3.484e-32 |
| 16 | CELL CYCLE G1 S PHASE TRANSITION | 24 | 111 | 1.241e-34 | 3.484e-32 |
| 17 | G1 S TRANSITION OF MITOTIC CELL CYCLE | 24 | 111 | 1.241e-34 | 3.484e-32 |
| 18 | REGULATION OF PROTEIN MODIFICATION PROCESS | 53 | 1710 | 5.71e-34 | 1.476e-31 |
| 19 | NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 24 | 146 | 1.582e-31 | 3.874e-29 |
| 20 | POSITIVE REGULATION OF CELL CYCLE | 30 | 332 | 1.995e-31 | 4.641e-29 |
| 21 | MITOTIC NUCLEAR DIVISION | 30 | 361 | 2.529e-30 | 5.603e-28 |
| 22 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 26 | 247 | 6.602e-29 | 1.396e-26 |
| 23 | DNA INTEGRITY CHECKPOINT | 22 | 146 | 5.082e-28 | 1.028e-25 |
| 24 | ORGANELLE FISSION | 31 | 496 | 1.509e-27 | 2.926e-25 |
| 25 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 40 | 1087 | 3.259e-27 | 6.066e-25 |
| 26 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 32 | 616 | 5.831e-26 | 1.044e-23 |
| 27 | REGULATION OF ORGANELLE ORGANIZATION | 39 | 1178 | 9.039e-25 | 1.558e-22 |
| 28 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 32 | 720 | 7.195e-24 | 1.196e-21 |
| 29 | REGULATION OF CELL DIVISION | 23 | 272 | 2.432e-23 | 3.901e-21 |
| 30 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 41 | 1492 | 4.207e-23 | 6.525e-21 |
| 31 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 19 | 147 | 6.364e-23 | 9.553e-21 |
| 32 | NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 17 | 98 | 7.18e-23 | 1.044e-20 |
| 33 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 42 | 1618 | 8.677e-23 | 1.223e-20 |
| 34 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 24 | 351 | 3.806e-22 | 5.209e-20 |
| 35 | REGULATION OF CELL CYCLE ARREST | 17 | 108 | 4.181e-22 | 5.558e-20 |
| 36 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 36 | 1135 | 4.59e-22 | 5.933e-20 |
| 37 | REGULATION OF NUCLEAR DIVISION | 19 | 163 | 4.863e-22 | 6.116e-20 |
| 38 | CHROMOSOME ORGANIZATION | 34 | 1009 | 1.406e-21 | 1.722e-19 |
| 39 | G1 DNA DAMAGE CHECKPOINT | 15 | 73 | 1.819e-21 | 2.171e-19 |
| 40 | SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 16 | 96 | 2.849e-21 | 3.314e-19 |
| 41 | MITOTIC DNA INTEGRITY CHECKPOINT | 16 | 100 | 5.711e-21 | 6.481e-19 |
| 42 | REGULATION OF KINASE ACTIVITY | 30 | 776 | 1.368e-20 | 1.516e-18 |
| 43 | POSITIVE REGULATION OF CELL CYCLE ARREST | 15 | 85 | 2.158e-20 | 2.335e-18 |
| 44 | CELL CYCLE G2 M PHASE TRANSITION | 17 | 138 | 3.291e-20 | 3.427e-18 |
| 45 | REGULATION OF SISTER CHROMATID SEGREGATION | 14 | 67 | 3.315e-20 | 3.427e-18 |
| 46 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 27 | 616 | 7.132e-20 | 7.214e-18 |
| 47 | REGULATION OF PROTEIN CATABOLIC PROCESS | 23 | 393 | 1.056e-19 | 1.045e-17 |
| 48 | REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 15 | 97 | 1.781e-19 | 1.726e-17 |
| 49 | CELL CYCLE ARREST | 17 | 154 | 2.247e-19 | 2.134e-17 |
| 50 | POSITIVE REGULATION OF PROTEOLYSIS | 22 | 363 | 3.5e-19 | 3.257e-17 |
| 51 | REGULATION OF LIGASE ACTIVITY | 16 | 130 | 4.648e-19 | 4.081e-17 |
| 52 | REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 20 | 274 | 4.602e-19 | 4.081e-17 |
| 53 | REGULATION OF CELL PROLIFERATION | 37 | 1496 | 4.565e-19 | 4.081e-17 |
| 54 | REGULATION OF CHROMOSOME ORGANIZATION | 20 | 278 | 6.132e-19 | 5.284e-17 |
| 55 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 29 | 829 | 1.056e-18 | 8.935e-17 |
| 56 | DNA METABOLIC PROCESS | 28 | 758 | 1.167e-18 | 9.695e-17 |
| 57 | REGULATION OF CHROMOSOME SEGREGATION | 14 | 85 | 1.208e-18 | 9.861e-17 |
| 58 | CELLULAR RESPONSE TO STRESS | 37 | 1565 | 2.046e-18 | 1.641e-16 |
| 59 | REGULATION OF PROTEOLYSIS | 27 | 711 | 2.765e-18 | 2.181e-16 |
| 60 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 23 | 470 | 5.627e-18 | 4.364e-16 |
| 61 | POSITIVE REGULATION OF MITOTIC CELL CYCLE | 15 | 123 | 7.369e-18 | 5.621e-16 |
| 62 | POSITIVE REGULATION OF CELL DEATH | 25 | 605 | 8.766e-18 | 6.579e-16 |
| 63 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 31 | 1079 | 1.35e-17 | 9.97e-16 |
| 64 | ANAPHASE PROMOTING COMPLEX DEPENDENT CATABOLIC PROCESS | 13 | 77 | 1.572e-17 | 1.143e-15 |
| 65 | CHROMOSOME SEGREGATION | 18 | 272 | 1.842e-16 | 1.315e-14 |
| 66 | NUCLEAR CHROMOSOME SEGREGATION | 17 | 228 | 1.866e-16 | 1.315e-14 |
| 67 | POSITIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 16 | 192 | 2.646e-16 | 1.838e-14 |
| 68 | PROTEIN PHOSPHORYLATION | 28 | 944 | 3.4e-16 | 2.327e-14 |
| 69 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 34 | 1518 | 4.3e-16 | 2.858e-14 |
| 70 | SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 14 | 127 | 4.248e-16 | 2.858e-14 |
| 71 | REGULATION OF CATABOLIC PROCESS | 25 | 731 | 7.265e-16 | 4.761e-14 |
| 72 | REGULATION OF PROTEIN UBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 13 | 103 | 8.35e-16 | 5.396e-14 |
| 73 | POSITIVE REGULATION OF CELL PROLIFERATION | 26 | 814 | 8.644e-16 | 5.51e-14 |
| 74 | PROTEIN UBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 14 | 134 | 9.144e-16 | 5.75e-14 |
| 75 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 19 | 360 | 1.589e-15 | 9.729e-14 |
| 76 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 36 | 1805 | 1.584e-15 | 9.729e-14 |
| 77 | SISTER CHROMATID SEGREGATION | 15 | 176 | 1.741e-15 | 1.052e-13 |
| 78 | POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 17 | 263 | 2.037e-15 | 1.2e-13 |
| 79 | POSITIVE REGULATION OF LIGASE ACTIVITY | 13 | 110 | 2.018e-15 | 1.2e-13 |
| 80 | RESPONSE TO ABIOTIC STIMULUS | 28 | 1024 | 2.675e-15 | 1.556e-13 |
| 81 | NEGATIVE REGULATION OF CHROMOSOME SEGREGATION | 9 | 28 | 2.911e-15 | 1.672e-13 |
| 82 | POSITIVE REGULATION OF GENE EXPRESSION | 35 | 1733 | 3.18e-15 | 1.804e-13 |
| 83 | REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 17 | 280 | 5.759e-15 | 3.228e-13 |
| 84 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 35 | 1791 | 8.621e-15 | 4.763e-13 |
| 85 | POSITIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 15 | 196 | 8.7e-15 | 4.763e-13 |
| 86 | POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 11 | 68 | 8.92e-15 | 4.826e-13 |
| 87 | REGULATION OF CELL DEATH | 32 | 1472 | 1e-14 | 5.349e-13 |
| 88 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 21 | 541 | 1.912e-14 | 9.995e-13 |
| 89 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 21 | 541 | 1.912e-14 | 9.995e-13 |
| 90 | DNA REPLICATION | 15 | 208 | 2.101e-14 | 1.086e-12 |
| 91 | NEGATIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 9 | 34 | 2.163e-14 | 1.106e-12 |
| 92 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 21 | 552 | 2.835e-14 | 1.434e-12 |
| 93 | POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 10 | 53 | 3.017e-14 | 1.509e-12 |
| 94 | RESPONSE TO OXYGEN LEVELS | 17 | 311 | 3.244e-14 | 1.606e-12 |
| 95 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 9 | 36 | 3.854e-14 | 1.888e-12 |
| 96 | NEGATIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 13 | 139 | 4.469e-14 | 2.166e-12 |
| 97 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 21 | 573 | 5.874e-14 | 2.818e-12 |
| 98 | PROTEASOMAL PROTEIN CATABOLIC PROCESS | 16 | 271 | 6.042e-14 | 2.869e-12 |
| 99 | SISTER CHROMATID COHESION | 12 | 111 | 7.716e-14 | 3.627e-12 |
| 100 | REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 13 | 148 | 1.015e-13 | 4.721e-12 |
| 101 | NEGATIVE REGULATION OF CELL DIVISION | 10 | 60 | 1.137e-13 | 5.24e-12 |
| 102 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 9 | 43 | 2.251e-13 | 1.027e-11 |
| 103 | PHOSPHORYLATION | 28 | 1228 | 2.447e-13 | 1.105e-11 |
| 104 | DNA REPAIR | 19 | 480 | 2.829e-13 | 1.266e-11 |
| 105 | PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 24 | 873 | 3.637e-13 | 1.612e-11 |
| 106 | NEGATIVE REGULATION OF PHOSPHORYLATION | 18 | 422 | 3.684e-13 | 1.617e-11 |
| 107 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 27 | 1152 | 3.857e-13 | 1.677e-11 |
| 108 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 8 | 29 | 4.432e-13 | 1.858e-11 |
| 109 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 8 | 29 | 4.432e-13 | 1.858e-11 |
| 110 | DNA REPLICATION INITIATION | 8 | 29 | 4.432e-13 | 1.858e-11 |
| 111 | NEGATIVE REGULATION OF NUCLEAR DIVISION | 9 | 46 | 4.351e-13 | 1.858e-11 |
| 112 | REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 13 | 181 | 1.367e-12 | 5.68e-11 |
| 113 | POSITIVE REGULATION OF CATABOLIC PROCESS | 17 | 395 | 1.556e-12 | 6.409e-11 |
| 114 | REGULATION OF DNA METABOLIC PROCESS | 16 | 340 | 1.966e-12 | 8.023e-11 |
| 115 | INTRACELLULAR SIGNAL TRANSDUCTION | 30 | 1572 | 2.605e-12 | 1.054e-10 |
| 116 | REGULATION OF FIBROBLAST PROLIFERATION | 10 | 81 | 2.627e-12 | 1.054e-10 |
| 117 | NEGATIVE REGULATION OF CELL PROLIFERATION | 20 | 643 | 5.174e-12 | 2.058e-10 |
| 118 | CELL DEATH | 24 | 1001 | 6.665e-12 | 2.628e-10 |
| 119 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 16 | 370 | 7.055e-12 | 2.759e-10 |
| 120 | PEPTIDYL AMINO ACID MODIFICATION | 22 | 841 | 1.122e-11 | 4.35e-10 |
| 121 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 31 | 1784 | 1.132e-11 | 4.353e-10 |
| 122 | SPINDLE CHECKPOINT | 7 | 25 | 1.224e-11 | 4.667e-10 |
| 123 | CELLULAR RESPONSE TO UV | 9 | 66 | 1.36e-11 | 5.144e-10 |
| 124 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 32 | 1929 | 1.576e-11 | 5.912e-10 |
| 125 | REGULATION OF MEMBRANE PERMEABILITY | 9 | 70 | 2.355e-11 | 8.767e-10 |
| 126 | CELLULAR RESPONSE TO RADIATION | 11 | 137 | 2.404e-11 | 8.879e-10 |
| 127 | RESPONSE TO LIPID | 22 | 888 | 3.221e-11 | 1.18e-09 |
| 128 | POSITIVE REGULATION OF CELL COMMUNICATION | 28 | 1532 | 4.904e-11 | 1.783e-09 |
| 129 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 23 | 1004 | 5.025e-11 | 1.813e-09 |
| 130 | POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 8 | 50 | 5.139e-11 | 1.84e-09 |
| 131 | NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 10 | 109 | 5.39e-11 | 1.915e-09 |
| 132 | RESPONSE TO DRUG | 16 | 431 | 6.87e-11 | 2.422e-09 |
| 133 | PROTEIN CATABOLIC PROCESS | 18 | 579 | 7.055e-11 | 2.468e-09 |
| 134 | NEGATIVE REGULATION OF KINASE ACTIVITY | 13 | 250 | 8.062e-11 | 2.799e-09 |
| 135 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 23 | 1036 | 9.376e-11 | 3.208e-09 |
| 136 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 23 | 1036 | 9.376e-11 | 3.208e-09 |
| 137 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 17 | 514 | 9.837e-11 | 3.341e-09 |
| 138 | REGULATION OF PROTEIN LOCALIZATION | 22 | 950 | 1.176e-10 | 3.966e-09 |
| 139 | POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 7 | 34 | 1.326e-10 | 4.407e-09 |
| 140 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 19 | 684 | 1.317e-10 | 4.407e-09 |
| 141 | REGULATION OF DNA REPLICATION | 11 | 161 | 1.387e-10 | 4.576e-09 |
| 142 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 31 | 1977 | 1.55e-10 | 5.079e-09 |
| 143 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 27 | 1517 | 2.198e-10 | 7.101e-09 |
| 144 | REGULATION OF INTRACELLULAR TRANSPORT | 18 | 621 | 2.193e-10 | 7.101e-09 |
| 145 | RESPONSE TO UV | 10 | 126 | 2.291e-10 | 7.302e-09 |
| 146 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 10 | 126 | 2.291e-10 | 7.302e-09 |
| 147 | CELLULAR RESPONSE TO LIGHT STIMULUS | 9 | 91 | 2.631e-10 | 8.272e-09 |
| 148 | MITOTIC SISTER CHROMATID SEGREGATION | 9 | 91 | 2.631e-10 | 8.272e-09 |
| 149 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 11 | 171 | 2.65e-10 | 8.277e-09 |
| 150 | PROTEIN UBIQUITINATION | 18 | 629 | 2.694e-10 | 8.358e-09 |
| 151 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 9 | 92 | 2.906e-10 | 8.954e-09 |
| 152 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 22 | 1008 | 3.62e-10 | 1.108e-08 |
| 153 | RESPONSE TO RADIATION | 15 | 413 | 3.9e-10 | 1.186e-08 |
| 154 | NEGATIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 8 | 64 | 4.028e-10 | 1.217e-08 |
| 155 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 21 | 917 | 4.146e-10 | 1.245e-08 |
| 156 | NEGATIVE REGULATION OF CHROMOSOME ORGANIZATION | 9 | 96 | 4.275e-10 | 1.275e-08 |
| 157 | RESPONSE TO ENDOGENOUS STIMULUS | 26 | 1450 | 4.476e-10 | 1.326e-08 |
| 158 | RESPONSE TO STEROID HORMONE | 16 | 497 | 5.536e-10 | 1.63e-08 |
| 159 | DNA DEPENDENT DNA REPLICATION | 9 | 99 | 5.645e-10 | 1.652e-08 |
| 160 | MEIOTIC CELL CYCLE | 11 | 186 | 6.506e-10 | 1.892e-08 |
| 161 | CELL PROLIFERATION | 18 | 672 | 7.759e-10 | 2.242e-08 |
| 162 | POSITIVE REGULATION OF CHROMOSOME SEGREGATION | 6 | 25 | 1.083e-09 | 3.11e-08 |
| 163 | DIGESTIVE SYSTEM DEVELOPMENT | 10 | 148 | 1.119e-09 | 3.193e-08 |
| 164 | REPLICATIVE SENESCENCE | 5 | 12 | 1.203e-09 | 3.406e-08 |
| 165 | REGULATION OF CELLULAR RESPONSE TO STRESS | 18 | 691 | 1.208e-09 | 3.406e-08 |
| 166 | POSITIVE REGULATION OF CHROMOSOME ORGANIZATION | 10 | 150 | 1.276e-09 | 3.575e-08 |
| 167 | NEGATIVE REGULATION OF ORGANELLE ORGANIZATION | 14 | 387 | 1.672e-09 | 4.659e-08 |
| 168 | PROTEIN K11 LINKED UBIQUITINATION | 6 | 27 | 1.797e-09 | 4.977e-08 |
| 169 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 15 | 465 | 1.98e-09 | 5.45e-08 |
| 170 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 12 | 263 | 2.013e-09 | 5.51e-08 |
| 171 | NEGATIVE REGULATION OF DNA REPLICATION | 7 | 55 | 4.638e-09 | 1.262e-07 |
| 172 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 9 | 128 | 5.599e-09 | 1.515e-07 |
| 173 | G2 DNA DAMAGE CHECKPOINT | 6 | 33 | 6.581e-09 | 1.77e-07 |
| 174 | POSITIVE REGULATION OF CELL DIVISION | 9 | 132 | 7.345e-09 | 1.964e-07 |
| 175 | REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 7 | 59 | 7.686e-09 | 2.044e-07 |
| 176 | REGULATION OF MICROTUBULE BASED PROCESS | 11 | 243 | 1.078e-08 | 2.841e-07 |
| 177 | RESPONSE TO HORMONE | 19 | 893 | 1.081e-08 | 2.841e-07 |
| 178 | POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 6 | 36 | 1.145e-08 | 2.993e-07 |
| 179 | POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 8 | 100 | 1.487e-08 | 3.866e-07 |
| 180 | REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 7 | 67 | 1.904e-08 | 4.921e-07 |
| 181 | MACROMOLECULE CATABOLIC PROCESS | 19 | 926 | 1.935e-08 | 4.975e-07 |
| 182 | RESPONSE TO GROWTH FACTOR | 14 | 475 | 2.252e-08 | 5.758e-07 |
| 183 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 10 | 203 | 2.355e-08 | 5.988e-07 |
| 184 | NEGATIVE REGULATION OF PROTEOLYSIS | 12 | 329 | 2.457e-08 | 6.213e-07 |
| 185 | MEIOTIC CELL CYCLE PROCESS | 9 | 152 | 2.525e-08 | 6.351e-07 |
| 186 | POSITIVE REGULATION OF KINASE ACTIVITY | 14 | 482 | 2.704e-08 | 6.764e-07 |
| 187 | REGULATION OF CELLULAR LOCALIZATION | 22 | 1277 | 2.798e-08 | 6.961e-07 |
| 188 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 10 | 207 | 2.834e-08 | 7.014e-07 |
| 189 | NEGATIVE REGULATION OF DNA METABOLIC PROCESS | 8 | 111 | 3.392e-08 | 8.35e-07 |
| 190 | REGULATION OF STEM CELL DIFFERENTIATION | 8 | 113 | 3.903e-08 | 9.558e-07 |
| 191 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 9 | 162 | 4.387e-08 | 1.069e-06 |
| 192 | PROTEIN SUMOYLATION | 8 | 115 | 4.479e-08 | 1.081e-06 |
| 193 | REGULATION OF CYTOSKELETON ORGANIZATION | 14 | 502 | 4.483e-08 | 1.081e-06 |
| 194 | REGULATION OF MITOCHONDRION ORGANIZATION | 10 | 218 | 4.623e-08 | 1.098e-06 |
| 195 | RESPONSE TO ESTROGEN | 10 | 218 | 4.623e-08 | 1.098e-06 |
| 196 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 10 | 218 | 4.623e-08 | 1.098e-06 |
| 197 | REGULATION OF BINDING | 11 | 283 | 5.154e-08 | 1.217e-06 |
| 198 | PROTEOLYSIS | 21 | 1208 | 5.328e-08 | 1.252e-06 |
| 199 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 9 | 167 | 5.704e-08 | 1.334e-06 |
| 200 | APOPTOTIC SIGNALING PATHWAY | 11 | 289 | 6.379e-08 | 1.484e-06 |
| 201 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 26 | 1848 | 7.009e-08 | 1.615e-06 |
| 202 | RESPONSE TO ALCOHOL | 12 | 362 | 7.002e-08 | 1.615e-06 |
| 203 | ORGAN REGENERATION | 7 | 83 | 8.581e-08 | 1.967e-06 |
| 204 | MITOCHONDRIAL TRANSPORT | 9 | 177 | 9.403e-08 | 2.145e-06 |
| 205 | NEGATIVE REGULATION OF GENE EXPRESSION | 23 | 1493 | 9.81e-08 | 2.227e-06 |
| 206 | REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 9 | 178 | 9.868e-08 | 2.229e-06 |
| 207 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 8 | 129 | 1.097e-07 | 2.467e-06 |
| 208 | REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE | 5 | 27 | 1.164e-07 | 2.604e-06 |
| 209 | PROTEIN POLYUBIQUITINATION | 10 | 243 | 1.279e-07 | 2.847e-06 |
| 210 | POSITIVE REGULATION OF DNA METABOLIC PROCESS | 9 | 185 | 1.372e-07 | 3.041e-06 |
| 211 | SMAD PROTEIN SIGNAL TRANSDUCTION | 6 | 56 | 1.778e-07 | 3.902e-06 |
| 212 | REPRODUCTION | 21 | 1297 | 1.77e-07 | 3.902e-06 |
| 213 | GLAND DEVELOPMENT | 12 | 395 | 1.8e-07 | 3.931e-06 |
| 214 | MITOTIC CELL CYCLE ARREST | 4 | 13 | 2.54e-07 | 5.524e-06 |
| 215 | REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS | 8 | 145 | 2.706e-07 | 5.856e-06 |
| 216 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 7 | 99 | 2.905e-07 | 6.229e-06 |
| 217 | REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 7 | 99 | 2.905e-07 | 6.229e-06 |
| 218 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 11 | 337 | 2.991e-07 | 6.383e-06 |
| 219 | PEPTIDYL SERINE MODIFICATION | 8 | 148 | 3.166e-07 | 6.726e-06 |
| 220 | REGULATION OF CELL AGING | 5 | 33 | 3.351e-07 | 7.087e-06 |
| 221 | POSITIVE REGULATION OF MITOTIC SISTER CHROMATID SEPARATION | 4 | 14 | 3.544e-07 | 7.396e-06 |
| 222 | POSITIVE REGULATION OF MITOTIC METAPHASE ANAPHASE TRANSITION | 4 | 14 | 3.544e-07 | 7.396e-06 |
| 223 | POSITIVE REGULATION OF METAPHASE ANAPHASE TRANSITION OF CELL CYCLE | 4 | 14 | 3.544e-07 | 7.396e-06 |
| 224 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 8 | 152 | 3.883e-07 | 8.065e-06 |
| 225 | CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 7 | 104 | 4.072e-07 | 8.42e-06 |
| 226 | NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 8 | 156 | 4.734e-07 | 9.704e-06 |
| 227 | RESPONSE TO LIGHT STIMULUS | 10 | 280 | 4.733e-07 | 9.704e-06 |
| 228 | ACTIVATION OF ANAPHASE PROMOTING COMPLEX ACTIVITY | 4 | 15 | 4.817e-07 | 9.83e-06 |
| 229 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 21 | 1381 | 5.006e-07 | 1.017e-05 |
| 230 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 10 | 285 | 5.564e-07 | 1.126e-05 |
| 231 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 9 | 220 | 5.938e-07 | 1.196e-05 |
| 232 | REGENERATION | 8 | 161 | 6.019e-07 | 1.207e-05 |
| 233 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 11 | 363 | 6.241e-07 | 1.246e-05 |
| 234 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 10 | 289 | 6.319e-07 | 1.251e-05 |
| 235 | REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 8 | 162 | 6.309e-07 | 1.251e-05 |
| 236 | POSITIVE REGULATION OF TRANSPORT | 17 | 936 | 6.765e-07 | 1.334e-05 |
| 237 | MESENCHYME MORPHOGENESIS | 5 | 38 | 6.963e-07 | 1.367e-05 |
| 238 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 6 | 71 | 7.434e-07 | 1.447e-05 |
| 239 | CHROMATIN MODIFICATION | 13 | 539 | 7.411e-07 | 1.447e-05 |
| 240 | NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 7 | 115 | 8.073e-07 | 1.565e-05 |
| 241 | NEGATIVE REGULATION OF CELL AGING | 4 | 17 | 8.342e-07 | 1.606e-05 |
| 242 | RHYTHMIC PROCESS | 10 | 298 | 8.352e-07 | 1.606e-05 |
| 243 | CELLULAR RESPONSE TO LIPID | 12 | 457 | 8.476e-07 | 1.623e-05 |
| 244 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 15 | 740 | 8.654e-07 | 1.65e-05 |
| 245 | NEGATIVE REGULATION OF CELL GROWTH | 8 | 170 | 9.089e-07 | 1.726e-05 |
| 246 | REGULATION OF DNA DEPENDENT DNA REPLICATION | 5 | 41 | 1.029e-06 | 1.946e-05 |
| 247 | RESPONSE TO NITROGEN COMPOUND | 16 | 859 | 1.088e-06 | 2.05e-05 |
| 248 | REGULATION OF CELLULAR RESPONSE TO HEAT | 6 | 76 | 1.115e-06 | 2.092e-05 |
| 249 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 7 | 121 | 1.139e-06 | 2.128e-05 |
| 250 | PEPTIDYL LYSINE MODIFICATION | 10 | 312 | 1.265e-06 | 2.355e-05 |
| 251 | REGULATION OF CELL GROWTH | 11 | 391 | 1.292e-06 | 2.395e-05 |
| 252 | CHROMATIN ORGANIZATION | 14 | 663 | 1.297e-06 | 2.395e-05 |
| 253 | NEGATIVE REGULATION OF CELL DEATH | 16 | 872 | 1.324e-06 | 2.435e-05 |
| 254 | REGULATION OF RESPONSE TO STRESS | 21 | 1468 | 1.351e-06 | 2.474e-05 |
| 255 | RESPONSE TO INORGANIC SUBSTANCE | 12 | 479 | 1.386e-06 | 2.529e-05 |
| 256 | RESPONSE TO KETONE | 8 | 182 | 1.519e-06 | 2.761e-05 |
| 257 | PROTEIN LOCALIZATION TO CHROMOSOME | 5 | 45 | 1.654e-06 | 2.994e-05 |
| 258 | GROWTH | 11 | 410 | 2.046e-06 | 3.69e-05 |
| 259 | POSITIVE REGULATION OF DNA REPLICATION | 6 | 86 | 2.314e-06 | 4.119e-05 |
| 260 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 15 | 801 | 2.31e-06 | 4.119e-05 |
| 261 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 18 | 1142 | 2.319e-06 | 4.119e-05 |
| 262 | POSITIVE REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION | 5 | 48 | 2.294e-06 | 4.119e-05 |
| 263 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 12 | 505 | 2.397e-06 | 4.241e-05 |
| 264 | MEIOSIS I | 6 | 88 | 2.648e-06 | 4.667e-05 |
| 265 | AGING | 9 | 264 | 2.688e-06 | 4.719e-05 |
| 266 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS | 4 | 23 | 3.041e-06 | 5.299e-05 |
| 267 | POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS | 4 | 23 | 3.041e-06 | 5.299e-05 |
| 268 | POSITIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 5 | 51 | 3.114e-06 | 5.406e-05 |
| 269 | MICROTUBULE CYTOSKELETON ORGANIZATION | 10 | 348 | 3.362e-06 | 5.815e-05 |
| 270 | CELLULAR RESPONSE TO OXYGEN LEVELS | 7 | 143 | 3.483e-06 | 6.002e-05 |
| 271 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 7 | 144 | 3.648e-06 | 6.263e-05 |
| 272 | RESPONSE TO IONIZING RADIATION | 7 | 145 | 3.819e-06 | 6.533e-05 |
| 273 | RESPONSE TO ESTRADIOL | 7 | 146 | 3.997e-06 | 6.812e-05 |
| 274 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 6 | 95 | 4.142e-06 | 7.034e-05 |
| 275 | HISTONE PHOSPHORYLATION | 4 | 25 | 4.315e-06 | 7.301e-05 |
| 276 | REGULATION OF GROWTH | 13 | 633 | 4.369e-06 | 7.366e-05 |
| 277 | CELLULAR CATABOLIC PROCESS | 19 | 1322 | 4.477e-06 | 7.521e-05 |
| 278 | POSITIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 6 | 98 | 4.964e-06 | 8.308e-05 |
| 279 | REGULATION OF CELLULAR SENESCENCE | 4 | 26 | 5.082e-06 | 8.475e-05 |
| 280 | CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 8 | 218 | 5.802e-06 | 9.642e-05 |
| 281 | CELLULAR RESPONSE TO HORMONE STIMULUS | 12 | 552 | 5.955e-06 | 9.825e-05 |
| 282 | REGULATION OF CELL MORPHOGENESIS | 12 | 552 | 5.955e-06 | 9.825e-05 |
| 283 | REGULATION OF CELL DIFFERENTIATION | 20 | 1492 | 6.813e-06 | 0.000112 |
| 284 | REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 4 | 28 | 6.913e-06 | 0.0001133 |
| 285 | REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION | 5 | 60 | 7.015e-06 | 0.0001145 |
| 286 | CELLULAR RESPONSE TO HYDROGEN PEROXIDE | 5 | 61 | 7.615e-06 | 0.0001239 |
| 287 | NEGATIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 4 | 29 | 7.992e-06 | 0.0001287 |
| 288 | REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 4 | 29 | 7.992e-06 | 0.0001287 |
| 289 | REGULATION OF HEART MORPHOGENESIS | 4 | 29 | 7.992e-06 | 0.0001287 |
| 290 | SOMITOGENESIS | 5 | 62 | 8.254e-06 | 0.000132 |
| 291 | POSITIVE REGULATION OF NUCLEAR DIVISION | 5 | 62 | 8.254e-06 | 0.000132 |
| 292 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 8 | 229 | 8.32e-06 | 0.0001326 |
| 293 | REGULATION OF PROTEIN ACETYLATION | 5 | 64 | 9.658e-06 | 0.0001529 |
| 294 | POSITIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS | 5 | 64 | 9.658e-06 | 0.0001529 |
| 295 | IMMUNE SYSTEM DEVELOPMENT | 12 | 582 | 1.015e-05 | 0.0001601 |
| 296 | NEGATIVE REGULATION OF GROWTH | 8 | 236 | 1.036e-05 | 0.0001629 |
| 297 | LENS DEVELOPMENT IN CAMERA TYPE EYE | 5 | 66 | 1.124e-05 | 0.0001761 |
| 298 | SENSORY ORGAN DEVELOPMENT | 11 | 493 | 1.179e-05 | 0.0001841 |
| 299 | NOTCH SIGNALING PATHWAY | 6 | 114 | 1.188e-05 | 0.0001849 |
| 300 | NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 4 | 32 | 1.198e-05 | 0.0001858 |
| 301 | CELL AGING | 5 | 67 | 1.211e-05 | 0.0001871 |
| 302 | NEGATIVE REGULATION OF CELLULAR SENESCENCE | 3 | 11 | 1.37e-05 | 0.0002103 |
| 303 | ACTIVATION OF MAPKKK ACTIVITY | 3 | 11 | 1.37e-05 | 0.0002103 |
| 304 | MITOTIC SPINDLE ORGANIZATION | 5 | 69 | 1.399e-05 | 0.0002141 |
| 305 | PROTEIN DESTABILIZATION | 4 | 34 | 1.534e-05 | 0.0002341 |
| 306 | EPITHELIUM DEVELOPMENT | 15 | 945 | 1.684e-05 | 0.000256 |
| 307 | RESPONSE TO MINERALOCORTICOID | 4 | 35 | 1.726e-05 | 0.0002608 |
| 308 | RESPONSE TO IRON ION | 4 | 35 | 1.726e-05 | 0.0002608 |
| 309 | RESPONSE TO METAL ION | 9 | 333 | 1.742e-05 | 0.0002615 |
| 310 | DEVELOPMENTAL GROWTH | 9 | 333 | 1.742e-05 | 0.0002615 |
| 311 | REGULATION OF PROTEIN IMPORT | 7 | 183 | 1.753e-05 | 0.0002623 |
| 312 | REGULATION OF MACROPHAGE CYTOKINE PRODUCTION | 3 | 12 | 1.82e-05 | 0.0002689 |
| 313 | POSITIVE REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS | 3 | 12 | 1.82e-05 | 0.0002689 |
| 314 | MITOTIC SISTER CHROMATID COHESION | 3 | 12 | 1.82e-05 | 0.0002689 |
| 315 | CELLULAR RESPONSE TO OXIDATIVE STRESS | 7 | 184 | 1.816e-05 | 0.0002689 |
| 316 | TRANSCRIPTION COUPLED NUCLEOTIDE EXCISION REPAIR | 5 | 73 | 1.844e-05 | 0.0002715 |
| 317 | MESENCHYME DEVELOPMENT | 7 | 190 | 2.233e-05 | 0.0003278 |
| 318 | RESPONSE TO REACTIVE OXYGEN SPECIES | 7 | 191 | 2.31e-05 | 0.0003379 |
| 319 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 8 | 264 | 2.326e-05 | 0.0003393 |
| 320 | POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 3 | 13 | 2.359e-05 | 0.000343 |
| 321 | REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS | 4 | 38 | 2.409e-05 | 0.0003492 |
| 322 | CATABOLIC PROCESS | 21 | 1773 | 2.533e-05 | 0.000366 |
| 323 | SOMITE DEVELOPMENT | 5 | 78 | 2.546e-05 | 0.0003668 |
| 324 | CELLULAR MACROMOLECULE LOCALIZATION | 17 | 1234 | 2.683e-05 | 0.0003853 |
| 325 | POSITIVE REGULATION OF P38MAPK CASCADE | 3 | 14 | 2.993e-05 | 0.0004284 |
| 326 | DNA GEOMETRIC CHANGE | 5 | 81 | 3.058e-05 | 0.0004365 |
| 327 | TISSUE DEVELOPMENT | 19 | 1518 | 3.163e-05 | 0.0004501 |
| 328 | TUBE DEVELOPMENT | 11 | 552 | 3.343e-05 | 0.0004742 |
| 329 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 19 | 1527 | 3.431e-05 | 0.0004852 |
| 330 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 20 | 1672 | 3.591e-05 | 0.0005063 |
| 331 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 12 | 662 | 3.616e-05 | 0.0005068 |
| 332 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 12 | 662 | 3.616e-05 | 0.0005068 |
| 333 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 8 | 282 | 3.721e-05 | 0.00052 |
| 334 | POSITIVE REGULATION OF CHROMATIN MODIFICATION | 5 | 85 | 3.861e-05 | 0.0005379 |
| 335 | HEART DEVELOPMENT | 10 | 466 | 4.205e-05 | 0.0005841 |
| 336 | REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS | 3 | 16 | 4.574e-05 | 0.0006297 |
| 337 | NEGATIVE REGULATION OF DNA DEPENDENT DNA REPLICATION | 3 | 16 | 4.574e-05 | 0.0006297 |
| 338 | CELLULAR RESPONSE TO ANTIBIOTIC | 3 | 16 | 4.574e-05 | 0.0006297 |
| 339 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 7 | 213 | 4.632e-05 | 0.0006358 |
| 340 | SEGMENTATION | 5 | 89 | 4.818e-05 | 0.0006594 |
| 341 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 9 | 381 | 4.991e-05 | 0.000681 |
| 342 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 13 | 799 | 5.094e-05 | 0.000691 |
| 343 | MESONEPHROS DEVELOPMENT | 5 | 90 | 5.084e-05 | 0.000691 |
| 344 | REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 7 | 217 | 5.211e-05 | 0.0007048 |
| 345 | REGULATION OF CYTOPLASMIC TRANSPORT | 10 | 481 | 5.484e-05 | 0.0007397 |
| 346 | POSITIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 3 | 17 | 5.537e-05 | 0.0007403 |
| 347 | POSITIVE REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 3 | 17 | 5.537e-05 | 0.0007403 |
| 348 | REGULATION OF SISTER CHROMATID COHESION | 3 | 17 | 5.537e-05 | 0.0007403 |
| 349 | REGULATION OF PROTEIN STABILITY | 7 | 221 | 5.848e-05 | 0.0007796 |
| 350 | REGULATION OF CHROMATIN ORGANIZATION | 6 | 152 | 6.034e-05 | 0.0008022 |
| 351 | REGULATION OF LIPID KINASE ACTIVITY | 4 | 48 | 6.138e-05 | 0.0008114 |
| 352 | HOMOLOGOUS CHROMOSOME SEGREGATION | 4 | 48 | 6.138e-05 | 0.0008114 |
| 353 | REGULATION OF DNA BIOSYNTHETIC PROCESS | 5 | 94 | 6.262e-05 | 0.0008254 |
| 354 | POSITIVE REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 3 | 18 | 6.623e-05 | 0.000868 |
| 355 | REGULATION OF UBIQUITIN PROTEIN LIGASE ACTIVITY | 3 | 18 | 6.623e-05 | 0.000868 |
| 356 | REGULATION OF PROTEIN TARGETING | 8 | 307 | 6.765e-05 | 0.0008842 |
| 357 | HEAD DEVELOPMENT | 12 | 709 | 6.997e-05 | 0.000912 |
| 358 | RESPONSE TO PROGESTERONE | 4 | 50 | 7.216e-05 | 0.0009353 |
| 359 | RESPONSE TO GAMMA RADIATION | 4 | 50 | 7.216e-05 | 0.0009353 |
| 360 | HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 5 | 98 | 7.639e-05 | 0.0009874 |
| 361 | RESPONSE TO AMMONIUM ION | 4 | 51 | 7.804e-05 | 0.001006 |
| 362 | REGULATION OF CELL DEVELOPMENT | 13 | 836 | 8.064e-05 | 0.001037 |
| 363 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 11 | 609 | 8.093e-05 | 0.001037 |
| 364 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 9 | 406 | 8.127e-05 | 0.001039 |
| 365 | CELLULAR RESPONSE TO IONIZING RADIATION | 4 | 52 | 8.425e-05 | 0.001074 |
| 366 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 12 | 724 | 8.537e-05 | 0.001085 |
| 367 | INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 4 | 53 | 9.082e-05 | 0.001151 |
| 368 | NEGATIVE REGULATION OF CELL CYCLE ARREST | 3 | 20 | 9.193e-05 | 0.001162 |
| 369 | NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 5 | 102 | 9.24e-05 | 0.001165 |
| 370 | RESPONSE TO TOXIC SUBSTANCE | 7 | 241 | 0.0001006 | 0.001266 |
| 371 | POSITIVE REGULATION OF PROTEIN IMPORT | 5 | 104 | 0.0001013 | 0.001271 |
| 372 | EYE DEVELOPMENT | 8 | 326 | 0.0001027 | 0.001284 |
| 373 | CRANIAL SKELETAL SYSTEM DEVELOPMENT | 4 | 55 | 0.0001051 | 0.001311 |
| 374 | MICROTUBULE BASED PROCESS | 10 | 522 | 0.0001079 | 0.001343 |
| 375 | NEGATIVE REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 6 | 170 | 0.000112 | 0.00139 |
| 376 | EPITHELIAL TO MESENCHYMAL TRANSITION | 4 | 56 | 0.0001128 | 0.001395 |
| 377 | NEGATIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 3 | 22 | 0.0001234 | 0.001515 |
| 378 | ENDOCARDIAL CUSHION MORPHOGENESIS | 3 | 22 | 0.0001234 | 0.001515 |
| 379 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 17 | 1395 | 0.0001232 | 0.001515 |
| 380 | MACROMOLECULAR COMPLEX ASSEMBLY | 17 | 1398 | 0.0001265 | 0.001545 |
| 381 | RESPONSE TO HYDROGEN PEROXIDE | 5 | 109 | 0.0001265 | 0.001545 |
| 382 | POSITIVE REGULATION OF DNA BIOSYNTHETIC PROCESS | 4 | 59 | 0.0001383 | 0.001685 |
| 383 | RESPONSE TO INCREASED OXYGEN LEVELS | 3 | 23 | 0.0001414 | 0.001714 |
| 384 | RESPONSE TO HYPEROXIA | 3 | 23 | 0.0001414 | 0.001714 |
| 385 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 12 | 767 | 0.0001468 | 0.001774 |
| 386 | NUCLEOTIDE EXCISION REPAIR | 5 | 113 | 0.0001499 | 0.001806 |
| 387 | COVALENT CHROMATIN MODIFICATION | 8 | 345 | 0.0001516 | 0.001823 |
| 388 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 7 | 258 | 0.0001535 | 0.001841 |
| 389 | EMBRYO DEVELOPMENT | 13 | 894 | 0.0001574 | 0.001883 |
| 390 | POSITIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 3 | 24 | 0.0001611 | 0.001908 |
| 391 | POSITIVE REGULATION OF G1 S TRANSITION OF MITOTIC CELL CYCLE | 3 | 24 | 0.0001611 | 0.001908 |
| 392 | POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 3 | 24 | 0.0001611 | 0.001908 |
| 393 | CELL DEVELOPMENT | 17 | 1426 | 0.0001606 | 0.001908 |
| 394 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 10 | 554 | 0.0001752 | 0.002069 |
| 395 | LENS FIBER CELL DIFFERENTIATION | 3 | 25 | 0.0001825 | 0.002123 |
| 396 | CELLULAR RESPONSE TO TOXIC SUBSTANCE | 3 | 25 | 0.0001825 | 0.002123 |
| 397 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 3 | 25 | 0.0001825 | 0.002123 |
| 398 | POSITIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 3 | 25 | 0.0001825 | 0.002123 |
| 399 | EPITHELIAL CELL APOPTOTIC PROCESS | 3 | 25 | 0.0001825 | 0.002123 |
| 400 | PROTEIN LOCALIZATION TO ORGANELLE | 10 | 556 | 0.0001804 | 0.002123 |
| 401 | REGULATION OF CYTOKINE PRODUCTION | 10 | 563 | 0.0001995 | 0.002315 |
| 402 | MEIOTIC CHROMOSOME SEGREGATION | 4 | 65 | 0.0002016 | 0.002334 |
| 403 | RESPONSE TO CORTICOSTERONE | 3 | 26 | 0.0002057 | 0.002363 |
| 404 | REGULATION OF P38MAPK CASCADE | 3 | 26 | 0.0002057 | 0.002363 |
| 405 | TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 6 | 190 | 0.0002053 | 0.002363 |
| 406 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 5 | 121 | 0.0002064 | 0.002366 |
| 407 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 4 | 66 | 0.0002139 | 0.00244 |
| 408 | NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 4 | 66 | 0.0002139 | 0.00244 |
| 409 | DNA CONFORMATION CHANGE | 7 | 273 | 0.000217 | 0.002469 |
| 410 | DEVELOPMENTAL MATURATION | 6 | 193 | 0.0002234 | 0.002535 |
| 411 | POSITIVE REGULATION OF NEURON DEATH | 4 | 67 | 0.0002267 | 0.002561 |
| 412 | REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS | 4 | 67 | 0.0002267 | 0.002561 |
| 413 | ANTERIOR POSTERIOR PATTERN SPECIFICATION | 6 | 194 | 0.0002297 | 0.002588 |
| 414 | KIDNEY EPITHELIUM DEVELOPMENT | 5 | 125 | 0.0002401 | 0.002699 |
| 415 | POSITIVE REGULATION OF CELL DEVELOPMENT | 9 | 472 | 0.0002515 | 0.00282 |
| 416 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 8 | 372 | 0.0002529 | 0.002828 |
| 417 | NEGATIVE REGULATION OF DENDRITE DEVELOPMENT | 3 | 28 | 0.0002575 | 0.002873 |
| 418 | POSITIVE REGULATION OF BINDING | 5 | 127 | 0.0002585 | 0.002878 |
| 419 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 12 | 823 | 0.0002809 | 0.00312 |
| 420 | INTRACELLULAR STEROID HORMONE RECEPTOR SIGNALING PATHWAY | 4 | 71 | 0.0002835 | 0.003134 |
| 421 | ENDODERM DEVELOPMENT | 4 | 71 | 0.0002835 | 0.003134 |
| 422 | NUCLEOTIDE EXCISION REPAIR PREINCISION COMPLEX ASSEMBLY | 3 | 29 | 0.0002862 | 0.003149 |
| 423 | POSITIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 3 | 29 | 0.0002862 | 0.003149 |
| 424 | CELL MATURATION | 5 | 131 | 0.0002984 | 0.003275 |
| 425 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 16 | 1360 | 0.0002992 | 0.003275 |
| 426 | MITOCHONDRION ORGANIZATION | 10 | 594 | 0.000306 | 0.003343 |
| 427 | REGULATION OF TRANSPORT | 19 | 1804 | 0.0003108 | 0.003387 |
| 428 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 18 | 1656 | 0.0003149 | 0.003423 |
| 429 | ORGAN MORPHOGENESIS | 12 | 841 | 0.0003418 | 0.003706 |
| 430 | LYMPHOCYTE DIFFERENTIATION | 6 | 209 | 0.0003425 | 0.003706 |
| 431 | RESPONSE TO ETHANOL | 5 | 136 | 0.0003547 | 0.003829 |
| 432 | REGULATION OF PEPTIDASE ACTIVITY | 8 | 392 | 0.0003591 | 0.003868 |
| 433 | SALIVARY GLAND DEVELOPMENT | 3 | 32 | 0.0003848 | 0.004116 |
| 434 | ENDOCARDIAL CUSHION DEVELOPMENT | 3 | 32 | 0.0003848 | 0.004116 |
| 435 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA | 3 | 32 | 0.0003848 | 0.004116 |
| 436 | NEUROGENESIS | 16 | 1402 | 0.0004196 | 0.004478 |
| 437 | REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 3 | 33 | 0.0004219 | 0.004493 |
| 438 | RESPONSE TO PEPTIDE | 8 | 404 | 0.0004387 | 0.004661 |
| 439 | RAS PROTEIN SIGNAL TRANSDUCTION | 5 | 143 | 0.0004466 | 0.004733 |
| 440 | PROTEIN TARGETING | 8 | 406 | 0.0004533 | 0.004794 |
| 441 | NEGATIVE REGULATION OF CYTOSKELETON ORGANIZATION | 6 | 221 | 0.0004607 | 0.004856 |
| 442 | HEART VALVE DEVELOPMENT | 3 | 34 | 0.0004613 | 0.004856 |
| 443 | IN UTERO EMBRYONIC DEVELOPMENT | 7 | 311 | 0.0004763 | 0.005003 |
| 444 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 12 | 876 | 0.0004927 | 0.005164 |
| 445 | RESPONSE TO MONOAMINE | 3 | 35 | 0.0005029 | 0.005259 |
| 446 | RESPONSE TO TRANSITION METAL NANOPARTICLE | 5 | 148 | 0.0005224 | 0.00545 |
| 447 | POSITIVE REGULATION OF OSSIFICATION | 4 | 84 | 0.0005389 | 0.005609 |
| 448 | POSITIVE REGULATION OF PROTEIN ACETYLATION | 3 | 36 | 0.0005469 | 0.005667 |
| 449 | HEAD MORPHOGENESIS | 3 | 36 | 0.0005469 | 0.005667 |
| 450 | CHROMATIN REMODELING | 5 | 150 | 0.0005553 | 0.005734 |
| 451 | REGULATION OF GENE EXPRESSION EPIGENETIC | 6 | 229 | 0.0005558 | 0.005734 |
| 452 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 13 | 1021 | 0.0005653 | 0.00582 |
| 453 | REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 3 | 37 | 0.0005932 | 0.006093 |
| 454 | MULTICELLULAR ORGANISM REPRODUCTION | 11 | 768 | 0.000595 | 0.006098 |
| 455 | TRANSCRIPTION INITIATION FROM RNA POLYMERASE II PROMOTER | 5 | 153 | 0.0006076 | 0.006213 |
| 456 | TISSUE REMODELING | 4 | 87 | 0.0006154 | 0.006279 |
| 457 | MEMBRANE ORGANIZATION | 12 | 899 | 0.0006199 | 0.006312 |
| 458 | OVULATION CYCLE PROCESS | 4 | 88 | 0.0006425 | 0.006499 |
| 459 | POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 3 | 38 | 0.000642 | 0.006499 |
| 460 | OOCYTE DIFFERENTIATION | 3 | 38 | 0.000642 | 0.006499 |
| 461 | CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 5 | 156 | 0.0006634 | 0.006696 |
| 462 | B CELL DIFFERENTIATION | 4 | 89 | 0.0006705 | 0.006753 |
| 463 | CELLULAR RESPONSE TO NUTRIENT | 3 | 39 | 0.0006933 | 0.006952 |
| 464 | SPLEEN DEVELOPMENT | 3 | 39 | 0.0006933 | 0.006952 |
| 465 | REGULATION OF CELL MATRIX ADHESION | 4 | 90 | 0.0006993 | 0.006997 |
| 466 | REGULATION OF DEPHOSPHORYLATION | 5 | 158 | 0.0007028 | 0.007017 |
| 467 | REGULATION OF ORGAN MORPHOGENESIS | 6 | 242 | 0.0007419 | 0.007392 |
| 468 | POSITIVE REGULATION OF CELL MATRIX ADHESION | 3 | 40 | 0.0007471 | 0.007412 |
| 469 | RESPONSE TO CADMIUM ION | 3 | 40 | 0.0007471 | 0.007412 |
| 470 | NEGATIVE REGULATION OF CELL COMMUNICATION | 14 | 1192 | 0.0007589 | 0.007513 |
| 471 | REGULATION OF DNA BINDING | 4 | 93 | 0.000791 | 0.007814 |
| 472 | NEGATIVE REGULATION OF FAT CELL DIFFERENTIATION | 3 | 41 | 0.0008035 | 0.007904 |
| 473 | ANDROGEN RECEPTOR SIGNALING PATHWAY | 3 | 41 | 0.0008035 | 0.007904 |
| 474 | LYMPHOCYTE ACTIVATION | 7 | 342 | 0.0008344 | 0.00819 |
| 475 | POSTTRANSCRIPTIONAL REGULATION OF GENE EXPRESSION | 8 | 448 | 0.0008623 | 0.008447 |
| 476 | PROTEIN LOCALIZATION | 18 | 1805 | 0.000878 | 0.008582 |
| 477 | RESPONSE TO CARBOHYDRATE | 5 | 168 | 0.0009261 | 0.009015 |
| 478 | BETA CATENIN TCF COMPLEX ASSEMBLY | 3 | 43 | 0.0009243 | 0.009015 |
| 479 | CELL ACTIVATION | 9 | 568 | 0.0009535 | 0.009262 |
| 480 | RESPONSE TO VITAMIN | 4 | 98 | 0.0009623 | 0.009328 |
| 481 | BODY MORPHOGENESIS | 3 | 44 | 0.0009887 | 0.009544 |
| 482 | RESPONSE TO OXIDATIVE STRESS | 7 | 352 | 0.0009868 | 0.009544 |
| 483 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 4 | 99 | 0.0009994 | 0.009628 |
| 484 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 4 | 100 | 0.001038 | 0.009954 |
| 485 | PEPTIDYL TYROSINE DEPHOSPHORYLATION | 4 | 100 | 0.001038 | 0.009954 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY | 11 | 28 | 1.442e-19 | 1.34e-16 |
| 2 | ENZYME BINDING | 37 | 1737 | 6.307e-17 | 2.93e-14 |
| 3 | KINASE BINDING | 22 | 606 | 1.619e-14 | 5.014e-12 |
| 4 | PROTEIN KINASE ACTIVITY | 22 | 640 | 4.911e-14 | 1.141e-11 |
| 5 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 18 | 445 | 9.021e-13 | 1.676e-10 |
| 6 | KINASE ACTIVITY | 23 | 842 | 1.425e-12 | 1.831e-10 |
| 7 | PROTEIN COMPLEX BINDING | 24 | 935 | 1.576e-12 | 1.831e-10 |
| 8 | TRANSCRIPTION FACTOR BINDING | 19 | 524 | 1.33e-12 | 1.831e-10 |
| 9 | KINASE REGULATOR ACTIVITY | 13 | 186 | 1.937e-12 | 2e-10 |
| 10 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 6 | 12 | 5.917e-12 | 5.497e-10 |
| 11 | MACROMOLECULAR COMPLEX BINDING | 27 | 1399 | 3.529e-11 | 2.981e-09 |
| 12 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 23 | 992 | 3.953e-11 | 3.06e-09 |
| 13 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 7 | 30 | 5.09e-11 | 3.638e-09 |
| 14 | CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 6 | 34 | 7.963e-09 | 5.284e-07 |
| 15 | ADENYL NUCLEOTIDE BINDING | 23 | 1514 | 1.263e-07 | 7.823e-06 |
| 16 | KINASE INHIBITOR ACTIVITY | 7 | 89 | 1.394e-07 | 8.093e-06 |
| 17 | ENZYME REGULATOR ACTIVITY | 18 | 959 | 1.85e-07 | 1.011e-05 |
| 18 | RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 7 | 104 | 4.072e-07 | 2.101e-05 |
| 19 | CYCLIN BINDING | 4 | 19 | 1.349e-06 | 6.597e-05 |
| 20 | MOLECULAR FUNCTION REGULATOR | 20 | 1353 | 1.542e-06 | 7.164e-05 |
| 21 | STEROID HORMONE RECEPTOR BINDING | 6 | 81 | 1.626e-06 | 7.192e-05 |
| 22 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 9 | 264 | 2.688e-06 | 0.0001135 |
| 23 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR BINDING | 5 | 50 | 2.818e-06 | 0.0001138 |
| 24 | RIBONUCLEOTIDE BINDING | 23 | 1860 | 4.571e-06 | 0.0001769 |
| 25 | CORE PROMOTER BINDING | 7 | 152 | 5.216e-06 | 0.0001938 |
| 26 | ACTIVATING TRANSCRIPTION FACTOR BINDING | 5 | 57 | 5.435e-06 | 0.0001942 |
| 27 | NF KAPPAB BINDING | 4 | 30 | 9.19e-06 | 0.0003162 |
| 28 | P53 BINDING | 5 | 67 | 1.211e-05 | 0.0004016 |
| 29 | SMAD BINDING | 5 | 72 | 1.723e-05 | 0.0005521 |
| 30 | CULLIN FAMILY PROTEIN BINDING | 3 | 12 | 1.82e-05 | 0.0005637 |
| 31 | RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING | 4 | 36 | 1.935e-05 | 0.00058 |
| 32 | CHROMATIN BINDING | 10 | 435 | 2.347e-05 | 0.0006813 |
| 33 | ANDROGEN RECEPTOR BINDING | 4 | 39 | 2.675e-05 | 0.0007402 |
| 34 | DNA DEPENDENT ATPASE ACTIVITY | 5 | 79 | 2.709e-05 | 0.0007402 |
| 35 | LIGASE REGULATOR ACTIVITY | 3 | 14 | 2.993e-05 | 0.0007943 |
| 36 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING | 3 | 15 | 3.729e-05 | 0.0009622 |
| 37 | PROTEIN HETERODIMERIZATION ACTIVITY | 10 | 468 | 4.359e-05 | 0.001095 |
| 38 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 11 | 588 | 5.916e-05 | 0.001446 |
| 39 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 16 | 1199 | 7.011e-05 | 0.00167 |
| 40 | HISTONE KINASE ACTIVITY | 3 | 19 | 7.839e-05 | 0.001821 |
| 41 | DNA HELICASE ACTIVITY | 4 | 53 | 9.082e-05 | 0.002058 |
| 42 | HORMONE RECEPTOR BINDING | 6 | 168 | 0.0001049 | 0.002321 |
| 43 | R SMAD BINDING | 3 | 23 | 0.0001414 | 0.003056 |
| 44 | PROTEIN C TERMINUS BINDING | 6 | 186 | 0.0001829 | 0.003863 |
| 45 | RECEPTOR BINDING | 17 | 1476 | 0.0002421 | 0.004998 |
| 46 | BHLH TRANSCRIPTION FACTOR BINDING | 3 | 28 | 0.0002575 | 0.0052 |
| 47 | REGULATORY REGION NUCLEIC ACID BINDING | 12 | 818 | 0.0002657 | 0.005253 |
| 48 | ENZYME INHIBITOR ACTIVITY | 8 | 378 | 0.0002816 | 0.00545 |
| 49 | PROTEIN DOMAIN SPECIFIC BINDING | 10 | 624 | 0.000451 | 0.008551 |
| 50 | ATP DEPENDENT DNA HELICASE ACTIVITY | 3 | 34 | 0.0004613 | 0.008571 |
| 51 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 10 | 629 | 0.00048 | 0.008744 |
| 52 | BETA CATENIN BINDING | 4 | 84 | 0.0005389 | 0.009627 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | CHROMOSOME | 32 | 880 | 3.177e-21 | 1.856e-18 |
| 2 | CHROMOSOMAL REGION | 21 | 330 | 9.223e-19 | 2.693e-16 |
| 3 | TRANSCRIPTION FACTOR COMPLEX | 19 | 298 | 4.873e-17 | 9.485e-15 |
| 4 | TRANSFERASE COMPLEX | 25 | 703 | 2.942e-16 | 4.295e-14 |
| 5 | NUCLEAR CHROMOSOME | 22 | 523 | 7.824e-16 | 9.138e-14 |
| 6 | CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX | 9 | 31 | 8.404e-15 | 8.18e-13 |
| 7 | ANAPHASE PROMOTING COMPLEX | 8 | 22 | 3.386e-14 | 2.825e-12 |
| 8 | CHROMATIN | 19 | 441 | 6.249e-14 | 4.562e-12 |
| 9 | NUCLEAR UBIQUITIN LIGASE COMPLEX | 9 | 42 | 1.786e-13 | 1.159e-11 |
| 10 | CATALYTIC COMPLEX | 25 | 1038 | 1.972e-12 | 1.151e-10 |
| 11 | CULLIN RING UBIQUITIN LIGASE COMPLEX | 12 | 150 | 2.935e-12 | 1.558e-10 |
| 12 | PROTEIN KINASE COMPLEX | 10 | 90 | 7.746e-12 | 3.77e-10 |
| 13 | MICROTUBULE CYTOSKELETON | 24 | 1068 | 2.58e-11 | 1.159e-09 |
| 14 | SPINDLE | 14 | 289 | 3.657e-11 | 1.525e-09 |
| 15 | CHROMOSOME CENTROMERIC REGION | 11 | 174 | 3.193e-10 | 1.243e-08 |
| 16 | CONDENSED CHROMOSOME | 11 | 195 | 1.074e-09 | 3.921e-08 |
| 17 | UBIQUITIN LIGASE COMPLEX | 12 | 262 | 1.928e-09 | 6.624e-08 |
| 18 | CHROMOSOME TELOMERIC REGION | 10 | 162 | 2.699e-09 | 8.757e-08 |
| 19 | CONDENSED NUCLEAR CHROMOSOME | 8 | 85 | 4.06e-09 | 1.248e-07 |
| 20 | CENTROSOME | 14 | 487 | 3.075e-08 | 8.979e-07 |
| 21 | SPINDLE POLE | 8 | 126 | 9.14e-08 | 2.542e-06 |
| 22 | MICROTUBULE ORGANIZING CENTER | 15 | 623 | 9.655e-08 | 2.563e-06 |
| 23 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 10 | 237 | 1.013e-07 | 2.571e-06 |
| 24 | MCM COMPLEX | 4 | 11 | 1.18e-07 | 2.873e-06 |
| 25 | NUCLEAR CHROMOSOME TELOMERIC REGION | 8 | 132 | 1.311e-07 | 3.063e-06 |
| 26 | CONDENSED CHROMOSOME OUTER KINETOCHORE | 4 | 12 | 1.765e-07 | 3.964e-06 |
| 27 | CYTOSKELETAL PART | 22 | 1436 | 2.2e-07 | 4.758e-06 |
| 28 | CYTOSKELETON | 26 | 1967 | 2.422e-07 | 5.051e-06 |
| 29 | CONDENSED CHROMOSOME CENTROMERIC REGION | 7 | 102 | 3.565e-07 | 7.179e-06 |
| 30 | KINETOCHORE | 7 | 120 | 1.077e-06 | 2.028e-05 |
| 31 | CONDENSED NUCLEAR CHROMOSOME CENTROMERIC REGION | 4 | 18 | 1.069e-06 | 2.028e-05 |
| 32 | RNA POLYMERASE II TRANSCRIPTION FACTOR COMPLEX | 6 | 101 | 5.913e-06 | 0.0001079 |
| 33 | COHESIN COMPLEX | 3 | 11 | 1.37e-05 | 0.0002424 |
| 34 | NUCLEAR TRANSCRIPTION FACTOR COMPLEX | 6 | 127 | 2.199e-05 | 0.0003669 |
| 35 | NUCLEOLUS | 14 | 848 | 2.161e-05 | 0.0003669 |
| 36 | CARBOXY TERMINAL DOMAIN PROTEIN KINASE COMPLEX | 3 | 22 | 0.0001234 | 0.002002 |
| 37 | SPINDLE MIDZONE | 3 | 27 | 0.0002306 | 0.00364 |
| 38 | CYTOPLASMIC VESICLE PART | 10 | 601 | 0.0003358 | 0.00516 |
| 39 | SCF UBIQUITIN LIGASE COMPLEX | 3 | 34 | 0.0004613 | 0.006908 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | hsa04110_Cell_cycle | 89 | 128 | 3.716e-214 | 6.689e-212 | |
| 2 | hsa04114_Oocyte_meiosis | 26 | 114 | 3.279e-38 | 2.951e-36 | |
| 3 | hsa04115_p53_signaling_pathway | 18 | 69 | 1.082e-27 | 6.494e-26 | |
| 4 | hsa04350_TGF.beta_signaling_pathway | 16 | 85 | 3.516e-22 | 1.582e-20 | |
| 5 | hsa04914_Progesterone.mediated_oocyte_maturation | 15 | 87 | 3.136e-20 | 1.129e-18 | |
| 6 | hsa04390_Hippo_signaling_pathway | 16 | 154 | 7.515e-18 | 2.255e-16 | |
| 7 | hsa04151_PI3K_AKT_signaling_pathway | 19 | 351 | 9.999e-16 | 2.571e-14 | |
| 8 | hsa04120_Ubiquitin_mediated_proteolysis | 11 | 139 | 2.817e-11 | 6.338e-10 | |
| 9 | hsa04310_Wnt_signaling_pathway | 11 | 151 | 6.934e-11 | 1.387e-09 | |
| 10 | hsa04722_Neurotrophin_signaling_pathway | 8 | 127 | 9.719e-08 | 1.749e-06 | |
| 11 | hsa03030_DNA_replication | 5 | 36 | 5.267e-07 | 8.618e-06 | |
| 12 | hsa04520_Adherens_junction | 5 | 73 | 1.844e-05 | 0.0002766 | |
| 13 | hsa04010_MAPK_signaling_pathway | 8 | 268 | 2.59e-05 | 0.0003587 | |
| 14 | hsa04012_ErbB_signaling_pathway | 5 | 87 | 4.319e-05 | 0.0005553 | |
| 15 | hsa03420_Nucleotide_excision_repair | 4 | 45 | 4.748e-05 | 0.0005698 | |
| 16 | hsa04144_Endocytosis | 6 | 203 | 0.0002931 | 0.003298 | |
| 17 | hsa04630_Jak.STAT_signaling_pathway | 5 | 155 | 0.0006444 | 0.006823 | |
| 18 | hsa04330_Notch_signaling_pathway | 3 | 47 | 0.001199 | 0.01199 | |
| 19 | hsa04710_Circadian_rhythm_._mammal | 2 | 23 | 0.004662 | 0.04416 | |
| 20 | hsa04916_Melanogenesis | 3 | 101 | 0.01037 | 0.09335 | |
| 21 | hsa04720_Long.term_potentiation | 2 | 70 | 0.0389 | 0.3334 | |
| 22 | hsa04510_Focal_adhesion | 3 | 200 | 0.05991 | 0.4739 | |
| 23 | hsa04660_T_cell_receptor_signaling_pathway | 2 | 108 | 0.08361 | 0.6271 | |
| 24 | hsa04380_Osteoclast_differentiation | 2 | 128 | 0.1112 | 0.7608 | |
| 25 | hsa04360_Axon_guidance | 2 | 130 | 0.1141 | 0.7608 | |
| 26 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 2 | 168 | 0.1719 | 1 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|